Compare TransMedics Group Inc (TMDX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Tyson Foods, Inc. — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while Tyson Foods, Inc. trades at $57.25 (market cap $20.42B). The key difference: Tyson Foods, Inc. is far larger — about 8× TransMedics Group Inc's market cap, and Tyson Foods, Inc. pays a 3.52% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | TSN | |
|---|---|---|
Market Cap | $2.54B | $20.42B |
Sector | Technology | Consumer Staples |
52-Week High | $150.42 | $68.75 |
52-Week Low | $61.99 | $50.72 |
Enterprise Value | $2.94B | $28.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Tyson Foods (TSN) trades at $57.05, down 1.25% with neutral technical indicators. The company shows stable revenue near $54B but thin margins, with a 0.81% net income margin and elevated P/E of 45.67. Recent earnings beat expectations in Q1 2026, while analyst consensus is mixed with a $68.80 price target. Dividend payments continue at $0.51 quarterly.
TSN offers modest growth potential with analyst upside but faces margin pressure and competitive challenges. The stock's valuation appears stretched relative to earnings, while consistent dividends provide income support. Key risks include commodity cost volatility and execution in the competitive protein market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
